Recent Finacing
Recent Raise
Ceptur Therapeutics is a preclinical biotechnology company developing targeted oligonucleotide therapeutics using proprietary U1 Adaptor bivalent oligonucleotides that recruit U1 snRNP to modulate pre-mRNA gene expression.
